Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data SpyGlass Pharma, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
FY2025
Research and development
20
29.2
General and administrative
7.08
12.3
Operating expenses
27.1
41.4
Operating income
-27.1
-41.4
Interest income
1.32
3.11
Other non-operating income
-2.1
1.58
Pre-tax income
-29.2
-39.9
Income tax
0
0
Net income
-29.2
-39.9
EBITDA
-26.8
-40.8
EPS, basic
-16.31
-17.98
EPS, diluted
-16.31
-17.98
Shares, basic (weighted)
1.79
2.22
Shares, diluted (weighted)
1.79
2.22
Balance sheet
FY2025
FY2025
Cash and equivalents
16.3
96.4
Other current assets
0.72
0.9
Total current assets
17.4
109
Property, plant and equipment
2.17
2.34
Lease right-of-use assets
3.29
1.55
Other non-current assets
0.45
0.49
Total assets
23.3
116
Accounts payable
1.98
2.7
Accrued liabilities
1.28
2.18
Total current liabilities
7.79
8.58
Lease liabilities
3.46
1.58
Total liabilities
11.2
10.2
Paid-in capital
4.39
5.89
Retained earnings
-64.9
-105
Shareholders' equity
-60.5
-98.8
Total equity
-60.5
-98.8
Total liabilities and equity
23.3
116
Shares outstanding
2.2
2.2
Cash flow statement
FY2025
FY2025
Net income
-29.2
-39.9
Depreciation and amortization
0.27
0.61
Stock-based compensation
1.49
2.79
Deferred income tax
-6.53
-9.91
Change in payables
1.34
0.55
Cash from operations
-22
-32.7
Capital expenditures
-1.99
-0.79
Cash from investing
22.3
-11.8
Stock issued
0.19
0.17
Share buybacks
0
-1.45
Cash from financing
0.19
125
Net change in cash
0.42
80.1
Free cash flow
-24
-33.5
Income taxes paid
0.02
0
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $27.07 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-57.3%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
396.9%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
24.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
12.7x
Current assets / current liabilities.
Quick ratio
11.2x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
11.2x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$17.98
Net income per basic share, as reported (split-adjusted).
FCF per share
-$15.11
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$14.75
Cash from operations / diluted weighted shares.
Book value per share
-$44.85
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
FCF yield
-3.7%
Free cash flow / market cap.
Earnings yield
-4.4%
Net income / market cap (the inverse of P/E).
Shareholder yield
0.2%
(Dividends paid + share buybacks) / market cap.
Was SpyGlass Pharma, Inc. profitable in fiscal 2025?
No. It reported a net loss of $39.9M.
How much free cash flow did SpyGlass Pharma, Inc. generate in fiscal 2025?
Cash from operations of $32.7M minus capital expenditures of $789.0K left free cash flow of -$33.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.